Milestone Pharmaceuticals has announced today that its MSP-2017 intranasal calcium channel antagonist has been assigned the unique non-proprietary name “etripamil” by the United States Adopted Name (USAN) Council. The company is developing the etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Milestone CEO Philippe Douville commented, “We are pleased to have etripamil approved as the generic name for MSP-2017. The receipt of a USAN generic name is an exciting step forward as we continue to advance our NODE-1, Phase 2 clinical study with etripamil for paroxysmal supraventricular tachycardia. Etripamil could improve patients’ quality of life by allowing them to terminate their PSVT episodes at home and minimize inpatient hospital treatments and/or emergency room visits.”
The company announced positive Phase 1 results for MSP-2017 in November 2014 and in June 2015 announced that it had raised $17 million for Phase 2 development.
Read the Milestone Pharmaceuticals press release.
